Raymond James initiated coverage of BioMarin with a Market Perform rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMRN:
- BioMarin receives FDA orphan designation for HCM treatment
- BioMarin to present data showing LT benefit of Voxzogo on children’s growth
- Micron upgraded, PayPal downgraded: Wall Street’s top analyst calls
- BioMarin initiated with a Buy at UBS
- BioMarin receives positive CHMP opinion in Europe to expand use of VOXZOGO